Get the Stockscreener App
7.50
4.60%
0.33
Kodiak Sciences Inc stock is traded at $7.50, with a volume of 396.52K.
It is up +4.60% in the last 24 hours and down -13.29% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
See More
Previous Close:
$7.17
Open:
$7.24
24h Volume:
396.52K
Relative Volume:
0.90
Market Cap:
$394.68M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-1.9947
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-1.32%
1M Performance:
-13.29%
6M Performance:
+161.32%
1Y Performance:
+140.38%
1-Day Range:
$6.97
$7.54
1-Week Range:
$6.97
$9.14
52-Week Range:
$2.185
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
7.50 | 394.68M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Barclays PLC - Defense World
Short Interest in Kodiak Sciences Inc. (NASDAQ:KOD) Rises By 8.1% - Defense World
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Up 8.1% in December - MarketBeat
Jane Street Group LLC Has $90,000 Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing - MSN
Why These 24 Stocks Are Skyrocketing - Insider Monkey
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates - MSN
Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type - GlobeNewswire Inc.
Geode Capital Management LLC Acquires 12,783 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Barclays PLC - Defense World
Kodiak Sciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Crude Oil Surges 2%; Tesla Shares Plummet - Benzinga
Kodiak Sciences (NASDAQ:KOD) Shares Down 2.9%Here's What Happened - MarketBeat
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by State Street Corp - Defense World
Sanctuary Advisors LLC Reduces Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership - Yahoo Finance
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.5%Time to Sell? - MarketBeat
Kodiak Sciences (NASDAQ:KOD) Trading 6.7% HigherStill a Buy? - MarketBeat
Kodiak Sciences (NASDAQ:KOD) Shares Gap UpTime to Buy? - MarketBeat
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by Fmr LLC - Defense World
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead - Investing.com India
Critical Survey: Allogene Therapeutics (NASDAQ:ALLO) versus Kodiak Sciences (NASDAQ:KOD) - Defense World
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases - The Eastern Progress Online
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Simply Wall St
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential - MSN
Nona Biosciences Partners With Kodiak Sciences For Ophthalmic Antibody Discovery - Contract Pharma
Nona Biosciences, Kodiak Sciences partner on antibody therapies for ophthalmic diseases - Seeking Alpha
Nona Biosciences and Kodiak Sciences Inc. Partners on Next-Generation Antibody Therapies for Ophthalmic Diseases - Marketscreener.com
Kodiak Sciences Partners with Nona Biosciences for Novel Eye Disease Antibody Development - StockTitan
Kodiak stock rallies 32% after Jefferies upgrades to buy - MSN
Jefferies Upgrades Kodiak Sciences (KOD) - MSN
Pactiv Evergreen, RealReal, Kodiak Sciences And Other Big Stocks Moving Higher On Monday - Benzinga
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock - Yahoo Finance
Kodiak Sciences shares initiated with buy rating on positive outlook By Investing.com - Investing.com South Africa
Kodiak stock rallies 32% after Jefferies upgrades to buy (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences shares initiated with buy rating on positive outlook - Investing.com
Kodiak Sciences (NASDAQ:KOD) Upgraded to "Buy" at Jefferies Financial Group - MarketBeat
Jacobs Levy Equity Management Inc. Sells 118,375 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - MarketBeat
Kodiak Sciences stock hits 52-week high at $7.81 By Investing.com - Investing.com Canada
Kodiak Sciences stock hits 52-week high at $7.81 - Investing.com India
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):